Lipid Lowering Treatment and Follow Up in Recent Post Acute Coronary Syndrome Patients: Real-World Evidence from the Multicenter Observational Prospective - Post Acute Coronary Syndrome Italian Study (PACSI)

Pompilio Faggiano, Giuseppe Patti, Stefania Cercone, Laura Canullo, Roberta Rossini, Gian Piero Perna, Angela Pirillo, Francesco Fattirolli, Gianfranco Terrosu, Pier Luigi Temporelli, Alberico Catapano

Abstract


PURPOSE: 

Patients suffering from an acute coronary syndrome are at very high risk for recurrent events. Early targeted pharmacological intervention primarily aimed at controlling plasma LDL-cholesterol (LDL-C) levels can result in the reduction of recurrent cardiovascular events. This study aimed to evaluate real-life evidence from the Italian setting to document current practice of secondary prevention in patients after acute coronary syndrome (ACS), specifically assessing: (i) the rate of LDL-C target (<70 mg/dl) achievement after 6-10 weeks from index event and at later follow-up, (ii) the distance from LDL-C target during follow up, (iii) adherence rate and visit attendance.

METHODS 

Multicenter observational prospective clinical study ACS patients, evaluating target attainment rate at 6 weeks (V0) and 18 months (V2).

RESULTS

Approximately 97.4% patients enrolled (N=524) received statin-based therapy, and 3.6% received ezetimibe at discharge; mean LDL-C values decreased from 113.0±44.7 mg/dL at discharge to 71.3±26.5 mg/dl at V0. Among patients with known LDL-C for main time-points, 51.7% achieved target LDL-C at V0, 45.8% at V2. Among patients not reaching the target, the mean distance from target was 23.5±20.7 mg/dL. Attainment of target LDL-C was similar in patients receiving intensive or low-moderate statin-based treatment (approximately 50%). LDL-C target attainment was associated with lower LDL-C value at discharge and smoking status. Adherence to statin treatment was high (96.2%) throughout, similarly to medical appointment attendance at V2 (84.7%).

CONCLUSION

Despite most ACS patients receiving intensive statin-based regimens, only approximately half achieved LDL-C target, suggesting the need for further optimizing drug selection, combination and dosage. 


Keywords


LDL-C; lipid lowering treatment; statins; ezetimibe; acute coronary syndrome; ESC/EAS guidelines

Full Text:

639-Faggiano

References


Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711- 8. doi:10.1001/jama.285.13.1711

Ray KK, Cannon CP, McCabe CH, for the PROVE IT-TIMI 22 Investigators. Early and late benefits of high- dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1405–10. DOI: 10.1016/j.jacc.2005.03.077

Collins R, Armitage J, Parish S, et al. for the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–16. DOI: 10.1016/s0140-6736(03)13636-7

GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J. 2001;141(2):190-9. https://doi.org/10.1067/mhj.2001.112404

Catapano AL, Graham I, De Backer G, et al. for the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37: 2999-3058. DOI:10.1093/eurheartj/ehw272

Reiner Z, Catapano A, De Backer G, et al. for the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2011; 32:1769–1818. doi:10.1093/eurheartj/ehr158

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol, Journal of the American College of Cardiology (2018), doi: https://doi.org/10.1016/j.jacc.2018.11.003.

Hirsh B, Smilowitz N, Rosenson R, et al. Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome Opportunities for Improvement. J Am Coll Cardiol. 2015; 66:184-92. http://dx.doi.org/10.1016/j.jacc.2015.05.030

Degli Espositi L, Sangiorgi D, Arca M, et al. Raggiungimento del target terapeutico nei soggetti avviati al trattamento con statine in pratica clinica. Risultati dallo studio STAR. Monaldi Arch Chest Dis. 2011;76:160-167. [article in Italian]

Riccio C, Gulizia, et al. ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy. European Heart Journal Supplements 19. 2017; (Supplement D): D163–D189 The Heart of the Matter doi:10.1093/eurheartj/sux021

Navarese E, Robinson J, Kowalewski M, et al. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. JAMA. 2018; 1566-1579. doi: 10.1001/jama.2018.2525.

Cannon CP, Blazing MA, Giugliano RP, et al., IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372:2387–2397. doi: 10.1056/NEJMoa1410489.

De Ferrari G, Perna GP, Nicosia A, et al. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dylipidemia International Study II-Italy. J Cardiovasc Med. 2018;19(9):485-490. doi: 10.2459/JCM.0000000000000680.

Ferrieres J, De Ferrari GM, Hermans MP, et al. Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. Eur J Prev Cardiol. 2018; 25(18):1966-1976. doi: 10.1177/2047487318806359.

Faggiano P, Pirillo A, Griffo R, et al. Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey. Int J Cardiol. 2018; 252:193-198. doi: 10.1016/j.ijcard.2017.10.105.

Soran H, Dent R, Durrington P. Evidence-based goals in LDL-C reduction. Clin Res Cardiol. 2017. 106:237–248 DOI 10.1007/s00392-016-1069-7.

Griffo R, Ambrosetti M, Tramarin R, et al. for the ICAROS investigators. Effective secondary prevention through cardiac rehabilitation after coronary revascularization and predictors of poor adherence to lifestyle modification and medication. Results of the ICAROS Survey. Int J Cardiol. 2013;167(4):1390-5. doi: 10.1016/j.ijcard.2012.04.069.

Gitt A, Lautsch D, Ferrieres J, et al. Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world. Data brief. 2018: 69–375. https://doi.org/10.1016/j.dib.2017.11.034

Jacobson T, Ito M, Maki K, et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1. Full Report. Journal of Clinical Lipidology. http://dx.doi.org/10.1016/j.jacl.2015.02.003

Shewan LG, Coats AJS, Henein MY. Authors’ Responsibilities and Ethical Publishing. International Cardiovascular Forum Journal 2018;13:3-4, DOI: 10.17987/icfj.v13i0.525




DOI: https://doi.org/10.17987/icfj.v19i0.639

Copyright (c) 2020 The author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.